Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

7.400 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,838
Open 7.400
Bid (Size) 7.350 (9)
Ask (Size) 7.360 (3)
Prev. Close 7.400
Today's Range 7.400 - 7.400
52wk Range 4.540 - 16.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Where Will Recursion Pharmaceuticals Be in 5 Years?
A lot is riding on whether its platform is valuable, or vaporware. 
Via The Motley Fool
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-25.03%
-25.03%
1 Month
-31.16%
-31.16%
3 Month
-25.18%
-25.18%
6 Month
+22.31%
+22.31%
1 Year
+23.95%
+23.95%

More News

Read More
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Via InvestorPlace
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024
Via InvestorPlace
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Recursion Pharmaceuticals
Via Benzinga
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Invest Sells $20M+ Coinbase Shares As Bitcoin Trades Over $70K, Buys Palantir, Sells Nvidia Stock
Via Benzinga
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Via The Motley Fool
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI Surge Ending: Only One Category Was Up This Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
AI Sector Stalling: Only 4 Of 7 Categories Went Up In March
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Invest Continues To Double Down On Moderna, Sells Nvidia Shares
Via Benzinga
Recursion Publishes Annual Environmental, Social and Governance Report
From Recursion Pharmaceuticals
Via GlobeNewswire
Nvidia's AI Revolution Is Transforming Healthcare with Johnson & Johnson and GE Healthcare Partnerships
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
New COVID-Like Outbreak 'Matter Of When, Not If,' WHO Director Warns As Scientists Race To Prepare Using Artificial Intelligence
Via Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Nvidia's Secret Weapon Is Not Just Chips But Investing $1.5B In AI's Rising Stars: Report Unveils CEO Jensen Huang's 10-Year Vision
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Announces Plans to Open New Office in London
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
Via The Motley Fool
The Top 7 Small-Cap Stocks to Buy in March 2024
Via InvestorPlace
Topics Economy
Exposures Interest Rates
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
Via InvestorPlace
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.